Sodium-Glucose Cotransporter-2 Inhibitors Therapy in Transthyretin Amyloid Cardiomyopathy: A Propensity-Matched Cohort Study.

Int J Heart Fail · 2026 · PMC13150454 · PMID 42110711

Europe PMC DOI

hedged sentence

0.1130

closest p · 2.3× alpha

0.1130

boldest claim

The sentences

did not reach statistical significancep=0.113not close (p > 0.1)

This benefit did not reach statistical significance in time-varying treatment-exposure Cox analyses in the matched cohort, either in the unadjusted model (HR, 0.42; 95% CI, 0.14–1.23; p=0.113) or after adjustment for relevant covariates (HR, 0.41; 95% CI, 0.11–1.48; p=0.174) ( Table 2 ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.